Xspray-logo-white
  • Home
  • About us
    • Business model
    • Our history – a timeline
    • Board of Directors & Board committees
    • Management
  • Technology
  • Pipeline
  • Media
  • Contact
  • Investors
  • en en
    • sv sv
  • Investors
    • Rights Issue 2023
    • Share information
      • Analysts
      • Trading information
      • Ownership structure
    • Financial calendar & Events
    • Financial reports
      • ESEF report
    • Prospectus
    • Press releases
    • Corporate governance
      • Corporate Structure
      • General meetings
      • Corporate Governance Reports
      • Nomination committee
      • Board of Directors & Board committees
      • Management
      • Accounting principles
      • Internal control & Risk management
      • Auditor
      • Articles of association
      • Remuneration

Press releases

All press releases Regulatory

Regulatory press release 2022-11-09

Interim Report Third Quarter 2022

Regulatory press release 2022-10-31

Number of shares and votes in Xspray Pharma

Regulatory press release 2022-10-25

Xspray Pharma’s Nomination Committee for the Annual General Meeting 2023

Regulatory press release 2022-10-17

Xspray Pharma has carried out a directed share issue raising proceeds of MSEK 100

Regulatory press release 2022-08-05

Interim Report Second Quarter 2022

Regulatory press release 2022-06-17

Dasynoc granted Orphan Drug Designation in the US for the treatment of chronic myeloid leukemia

Regulatory press release 2022-06-15

Xspray Pharma appoints Thomas Walz as Chief Medical Officer

Regulatory press release 2022-05-19

Bulletin from the 2022 Annual General Meeting of Xspray Pharma AB (publ)

Regulatory press release 2022-05-06

An eventful quarter sets the agenda for an intense 2022

Regulatory press release 2022-04-19

Notice of annual general meeting of Xspray Pharma AB (publ)

Show more

Subscribe

  • Submit to our press releases and get an email every time we publish a press release or report on our website.
  • When clicked on Send I agree that my personal information will be saved. Read more
  • This field is for validation purposes and should be left unchanged.

IR contact

Kerstin Hasselgren, Chief Financial Officer

+46 (0)70 311 16 83

info@xspray.com

Xspray-logo-white

Xspray Pharma AB Råsundavägen 12 169 67 Solna

+46 (0)8 730 37 00 info@xspraypharma.com